Clinical Trial Update: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma [Phase 3]

View source ↗

Summary

Open-label expanded access study update for the Melphalan/Hepatic Delivery System in hepatic-dominant ocular/uveal melanoma (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Melanoma
• Uveal Melanoma

Drugs mentioned

• Melphalan/Hepatic Delivery System (melphalan)

Snippet

Sponsor: Delcath Systems Inc. | Conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Phase 3 | Status: UNKNOWN